Pfizer Inc. announced today top-line results from a Phase
3B/4 study of RAPAMUNE® evaluating kidney transplant patients who transitioned
from tacrolimus-based therapy to RAPAMUNE® 3 to 5 months after transplant.
Pfizer Inc. (PFE), with a current value of $205.23B, started the session at
$30.88. Shares have traded today between $30.88 and $31.12 per share with a
trailing 52-week range being $23.55 to $31.40.
Pfizer (PFE) shares are currently priced at 14.21x this
year’s forecasted earnings, which makes them relatively expensive compared to
the industry’s -11.36x earnings multiple for the same period. And for income investors, the company pays
shareholders $0.96 per share annually in dividends, yielding 3.10%.
According to a consensus of 17 analysts, the earnings
estimate of $0.53 per share would be $0.06 better than the year-ago quarter and
a $0.00 sequential decrease. What we find to be interesting is that the
full-year EPS estimate of $2.18 is a $0.01 setback when compared to the
previous year’s annual results. Read more
No comments:
Post a Comment